Efficacy of human rotavirus vaccine against severe gastroenteritis in Malawian children in the first two years of life: A randomized, double-blind, placebo controlled trial

Vaccine

Volumn 30, Issue SUPPL. 1, 2012, Pages

  Cunliffe, Nigel A ^a   Witte, Desiree ^a,b   Ngwira, Bagrey M ^b   Todd, Stacy ^a   Bostock, Nancy J ^a   Turner, Ann M ^a   Chimpeni, Philips ^b   Victor, John C ^c   Steele, A Duncan ^c   Bouckenooghe, Alain ^d   Neuzil, Kathleen M ^c  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b UNIVERSITY OF MALAWI   (Malawi)

^c PATH   (United States)

^d Sanofi Pasteur ^*  (Singapore)

Author keywords

Gastroenteritis; Genotypes; Rotavirus; Vaccine

Indexed keywords

IMMUNOGLOBULIN A; PLACEBO; ROTAVIRUS VACCINE;

ARTICLE; CHILD; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; GENOTYPE; HUMAN; IMMUNOGENICITY; INFANT; MAJOR CLINICAL STUDY; MALAWI; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; PRESCHOOL CHILD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; ROTAVIRUS; SEROCONVERSION; VIRAL GASTROENTERITIS; VIRUS STRAIN;

ADMINISTRATION, ORAL; ANTIBODIES, VIRAL; DOUBLE-BLIND METHOD; ENZYME-LINKED IMMUNOSORBENT ASSAY; GASTROENTERITIS; GENOTYPE; HUMANS; IMMUNOGLOBULIN A; INFANT; MALAWI; PLACEBOS; ROTAVIRUS; ROTAVIRUS INFECTIONS; ROTAVIRUS VACCINES; SEVERITY OF ILLNESS INDEX; VACCINATION; VACCINES, ATTENUATED;

EID: 84859952555     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.09.120     Document Type: Article

References (42)

1. Black R.E., Cousens S., Johnson H.L., Lawn J.E., Rudan I., Bassani D.G., et al. Global, regional, and national causes of child mortality in 2008: a systematic analysis. Lancet 2010, 375:1969-1987.
2. Tate J.E., Burton A.H., Boschi-Pinto C., Steele A.D., Duque J., Parashar U.D., et al. 2008 estimate of worldwide rotavirus-associated mortality in children younger than 5 years before the introduction of universal rotavirus vaccination programmes: a systematic review and meta-analysis. Lancet Infect Dis 2012, 12(2):131-141.
3. World Health Organization The WHO position paper on rotavirus vaccines. Wkly Epidemiol Rec 2007, 82:285-296.
4. Sanchez-Padilla E., Grais R.F., Guerin P.J., Steele A.D., Burny M.E., Luquero F.J. Burden of disease and circulating serotypes of rotavirus infection in sub-Saharan Africa: systematic review and meta-analysis. Lancet Infect Dis 2009, 9:567-576.
5. Neuzil K.M., Armah G.E., Parashar U.D., Steele A.D. Rotavirus in Africa: shifting the focus to disease prevention. J Infect Dis 2010, 202:S1-S4.
6. Ruiz-Palacios G.M., Pérez-Schael I., Velázquez F.R., Abate H., Breuer T., Clemens S.C., et al. Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. N Engl J Med 2006, 354:11-22.
7. Vesikari T., Matson D.O., Dennehy P., Van Damme P., Santosham M., Rodriguez Z., et al. Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine. N Engl J Med 2006, 354:23-33.
8. Soares-Weiser K., MacLehose H., Ben-Aharon I., Goldberg E., Pitan F., Cunliffe N. Vaccines for preventing rotavirus diarrhoea. Part 1. Vaccines approved for use. Cochrane Database Syst Rev 2010, 5:CD008521.
9. World Health Organization Conclusions and recommendations from the Immunization Strategic Advisory Group. Wkly Epidemiol Rec 2006, 81:1-12.
10. Tate J.E., Patel M.M., Steele A.D., Gentsch J.R., Payne D.C., Cortese M.M., et al. Global impact of rotavirus vaccines. Exp Rev Vaccines 2010, 9:395-407.
11. Richardson V., Hernandez-Pichardo J., Quintanar-Solares M., Esparza-Aguilar M., Johnson B., Gomez-Altamirano C.M., et al. Effect of rotavirus vaccination on death from childhood diarrhea in Mexico. N Engl J Med 2010, 362:299-305.
12. Patel M.M., López-Collada V.R., Bulhões M.M., De Oliveira L.H., Bautista Márquez A., Flannery B., et al. Intussusception risk and health benefits of rotavirus vaccination in Mexico and Brazil. N Engl J Med 2011, 364:2283-2292.
13. World Health Organization Meeting of the immunization Strategic Advisory Group of Experts, April 2009-conclusions and recommendations. Wkly Epidemiol Rec 2009, 84:220-236.
14. Madhi S.A., Cunliffe N.A., Steele A.D., Witte D., Kirsten M., Louw C., et al. Effect of human rotavirus vaccine on severe gastroenteritis in African infants. N Engl J Med 2010, 362:289-298.
15. Ruuska T., Vesikari T. Rotavirus disease in Finnish children: use of numerical scores for clinical severity of diarrheal episodes. Scand J Infect Dis 1990, 22:259-267.
16. Van Doorn L.J., Kleter B., Hoefnagel E., Stainier I., Poliszczak A., Colau B., et al. Detection and genotyping of human rotavirus VP4 and VP7 genes by reverse transcriptase PCR and reverse hybridization. J Clin Microbiol 2009, 47:2704-2712.
17. Tang M.L., Ng H.K. Comment on: confidence limits for the ratio of two rates based on likelihood scores: non-iterative method. Stat Med 2004, 23:685-692.
18. Böhning D. Confidence interval estimation of a rate and the choice of sample size. Stat Med 1988, 7:865-875.
19. Zou G.Y., Donner A. Construction of confidence limits about effect measures: a general approach. Stat Med 2008, 27:1693-1702.
20. Armah G.E., Sow S.O., Breiman R.F., Dallas M.J., Tapia M.D., Feikin D.R., et al. Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in sub-Saharan Africa: a randomised, double-blind, placebo-controlled trial. Lancet 2010, 376:606-614.
21. Zaman K., Dang D.A., Victor J.C., Shin S., Yunus M., Dallas M.J., et al. Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in Asia: a randomised, double-blind, placebo-controlled trial. Lancet 2010, 376:615-623.
22. Cunliffe N.A., Ngwira B.M., Dove W., Thindwa B.D., Turner A.M., Broadhead R.L., et al. Epidemiology of rotavirus infection in children in Blantyre, Malawi, 1997-2007. J Infect Dis 2010, 202:S168-S174.
23. Madhi SA, Kirsten M, Louw C, Bos P, Aspinall S, Bouckenooghe A, et al. Efficacy and immunogenicity of two or three dose rotavirus-vaccine regimen in South African children over two consecutive rotavirus-seasons: a randomized, double-blind, placebo-controlled trial [this supplement]; in press.
24. Correia J.B., Patel M.M., Nakagomi O., Montenegro F.M.U., Germano E.M., Correia N.B., et al. Effectiveness of monovalent rotavirus vaccine (Rotarix) against severe diarrhoea caused by serotypically-unrelated G2P[4] strains in Brazil. J Infect Dis 2010, 201:363-369.
25. De Palma O., Cruz L., Ramos H., de Baires A., Villatoro N., Pastor D., et al. Effectiveness of rotavirus vaccination against childhood diarrhoea in El Salvador: case control study. BMJ 2010, 341:c2825.
26. Snelling T.L., Andrews R.M., Kirkwood C.D., Culvenor S., Carapetis J.R. Case-control evaluation of the effectiveness of the G1P[8] human rotavirus vaccine during an outbreak of rotavirus G2P[4] infection in central Australia. Clin Infect Dis 2011, 52:191-199.
27. Velázquez F.R., Matson D.O., Calva J.J., Guerrero L., Morrow A.L., Carter-Campbell S., et al. Rotavirus infections in infants as protection against subsequent infections. N Engl J Med 1996, 335:1022-1028.
28. Gladstone B.P., Ramani S., Mukhopadhya I., Muliyil J., Sarkar R., Rehman A.M., et al. Protective effect of natural rotavirus infection in an Indian birth cohort. N Engl J Med 2011, 365:337-346.
29. Vesikari T., Karvonen A., Prymula R., Schuster V., Tejedor J.C., Cohen R., et al. Efficacy of human rotavirus vaccine against rotavirus gastroenteritis during the first 2 years of life in European infants: randomised, double-blind controlled study. Lancet 2007, 370:1757-1763.
30. Linhares A.C., Velázquez F.R., Pérez-Schael I., Sáez-Llorens X., Abate H., Espinoza F., et al. Efficacy and safety of an oral live attenuated human rotavirus vaccine against rotavirus gastroenteritis during the first 2 years of life in Latin American infants: a randomized, double-blind, placebo-controlled phase III study. Lancet 2008, 371:1181-1189.
31. Phua K.B., Lim F.S., Lau Y.L., Nelson E.A.S., Huang L.M., Quak S.H., et al. Safety and efficacy of human rotavirus vaccine during the first 2 years of life in Asian infants: randomized, double-blind, controlled study. Vaccine 2009, 27:5936-5941.
32. Boom J.A., Tate J.E., Sahni L.C., Rench M.A., Quaye O., Mijatovic-Rustempasic S., et al. Sustained protection from pentavalent rotavirus vaccination during the second year of life at a large, urban United States pediatric hospital. Pediatr Infect Dis J 2010, 29:1133-1135.
33. Cunliffe N., Nakagomi O. Introduction of rotavirus vaccines in developing countries: remaining challenges. Ann Trop Paediatr 2007, 27:157-167.
34. Patel M., Shane A.L., Parashar U.D., Jiang B., Gentsch J.R., Glass R.I. Oral rotavirus vaccines: how well will they work where they are needed most?. J Infect Dis 2009, 200:S39-S48.
35. Jiang V., Jiang B., Tate J., Parashar U.D., Patel M.M. Performance of rotavirus vaccines in developed and developing countries. Hum Vaccines 2010, 6:532-542.
36. Ward R.L., Clark H.F., Offit P.A. Influence of potential protective mechanisms on the development of live rotavirus vaccines. J Infect Dis 2010, 202:S72-S79.
37. Desselberger U., Huppertz H.I. Immune responses to rotavirus infection and vaccination and associated correlates of protection. J Infect Dis 2011, 203:188-195.
38. Todd S., Page N.A., Steele A.D., Peenze I., Cunliffe N.A. Rotavirus strain types circulating In Africa: review of studies published from 1997 to 2006. J Infect Dis 2010, 202:S34-S42.
39. Nakagomi T, Nakagomi O, Dove W, Doan YH, Witte D, Ngwira B, et al. Molecular characterization of rotavirus strains detected during a clinical trial of a human rotavirus vaccine in Blantyre, Malawi [this supplement]; in press.
40. Neuzil K.M., Madhi S.A., Cunliffe N.A., Kirsten M., Bos P., Witte D., et al. RIX4414 is protective against severe rotavirus gastroenteritis caused by diverse rotavirus serotypes during the first year of life in African infants 2009, ESPID, Brussels.
41. Tate J.E., Cortese M.M., Payne D.C., Curns A.T., Yen C., Esposito D.H., et al. Uptake, impact, and effectiveness of rotavirus vaccination in the United States: review of the first 3 years of postlicensure data. Pediatr Infect Dis J 2011, 30:S56-S60.
42. Berry S.A., Johns B., Shih C., Berry A.A., Walker D.G. The cost-effectiveness of rotavirus vaccination in Malawi. J Infect Dis 2010, 202:S108-S115.